CAR T-CELL THERAPY

car t-cell therapy is highlighting the necessity for a more flexible and nimble process to introduce innovation into our health and cancer systems. And the urgent need for stakeholders to work collaboratively to accelerate introduction, while creating an approach that makes access available for all canadians, equitably. innovation brings with it an enormous amount of complexity to our systems and proactive planning is needed to meaningfully integrate and help us move toward more flexible pathways for innovative therapies to be introduced in canada. decision makers, payors and patients have been anticipating the arrival of car t-cell therapy and the impact and implications of what this means for paediatric and adult leukaemia and lymphoma.

​

enhancing patient access will require flexible thinking about how we introduce, pay for, implement and deliver car t-cell therapy across canada. what role do we want canada to play in car t-cell therapy delivery and what is each stakeholder’s responsibility in achieving.

​

how can stakeholders prioritize solutions that can enhance patient access to current and upcoming gene therapies through a multidisciplinary approach that can be adaptable as novel therapies and breakthroughs continue to be introduced.